Skip to content
10-Q

Quarterly Report

NRX Pharmaceuticals, Inc. NRXP

0001437749-25-027167

← back to feed
Filed
Aug 18, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 14, 2025 19.71M sh
Operating Cash Flow Q2 2024 · Jun 30, 2025 −$7.51M
Operating Cash Flow Q2 2024 · Jun 30, 2024 −$6.23M
Cash And Equivalents Q2 2024 · Jun 30, 2025 $2.91M
Cash And Equivalents Q2 2024 · Dec 31, 2024 $1.44M
Stockholders Equity Q2 2024 · Jun 30, 2025 −$35.62M
Stockholders Equity Q2 2024 · Mar 31, 2025 −$25.16M
Stockholders Equity Q2 2024 · Dec 31, 2024 −$23.22M
Stockholders Equity Q2 2024 · Jun 30, 2024 −$18.39M
Stockholders Equity Q2 2024 · Mar 31, 2024 −$15.07M
Stockholders Equity Q2 2024 · Dec 31, 2023 −$11.73M
Current Liabilities Q2 2024 · Jun 30, 2025 $40.45M
Current Liabilities Q2 2024 · Dec 31, 2024 $21.86M
Total Liabilities Q2 2024 · Jun 30, 2025 $40.45M
Total Liabilities Q2 2024 · Dec 31, 2024 $26.87M
Current Assets Q2 2024 · Jun 30, 2025 $4.59M
Current Assets Q2 2024 · Dec 31, 2024 $3.3M
Total Assets Q2 2024 · Jun 30, 2025 $4.84M
Total Assets Q2 2024 · Dec 31, 2024 $3.65M
Eps Basic Q2 2024 · Jun 30, 2025 −$0.98
Eps Basic Q2 2024 · Jun 30, 2025 −$1.34
Eps Basic Q2 2024 · Jun 30, 2024 −$0.75
Eps Basic Q2 2024 · Jun 30, 2024 −$1.49
Rd Expense Q2 2024 · Jun 30, 2025 $987K
Rd Expense Q2 2024 · Jun 30, 2025 $1.79M
Rd Expense Q2 2024 · Jun 30, 2024 $2.8M
Rd Expense Q2 2024 · Jun 30, 2024 $4.55M
Net Income Q2 2024 · Jun 30, 2025 −$17.58M
Net Income Q2 2024 · Jun 30, 2025 −$23.09M
Net Income Q2 2024 · Mar 31, 2025 −$5.51M
Net Income Q2 2024 · Jun 30, 2024 −$7.9M
Net Income Q2 2024 · Jun 30, 2024 −$14.43M
Net Income Q2 2024 · Mar 31, 2024 −$6.53M
Operating Income Q2 2024 · Jun 30, 2025 −$3.73M
Operating Income Q2 2024 · Jun 30, 2025 −$7.58M
Operating Income Q2 2024 · Jun 30, 2024 −$7.05M
Operating Income Q2 2024 · Jun 30, 2024 −$13.05M
Revenue Q2 2024 · Jun 30, 2025 $0